All In Biotech

Drug Trial Radar · NCT05457283

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 8, 2022

Primary completion

Aug 7, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jul 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and/or proteinuria. These include "angiotensin-converting enzyme inhibitors" (ACEI) and "angiotensin receptor blockers" (ARB). Both ACEI and ARB can help improve kidney function by reducing the activity of the renin-angiotensin-aldosterone system (RAAS). The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can impair the ability of the kidneys to work properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system. The study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB. So, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function. The main purpose of this study is to learn how safe the treatment is when used of finerenone in addition to an ACEI or ARB in long-term. To see how safe the treatment is, the study team will collect information on medical problems which are also known as "treatment emergent adverse events" (TEAEs). And they will also collect levels of an electrolyte called potassium in the blood by taking blood samples, and measure blood pressure during the study. The secondary purpose of this study is to learn how well long-term use of finerenone can reduce the amount of protein in the participants' urine and benefit kidney function when taken with standard of care. To see how the treatment works, the study team will collect participants' urine samples to assess urinary albumin-to-creatinine ratio (UACR) and urinary protein-to-creatinine ratio (UPCR), which are important assessments for calculating the level of protein in the urine. Researchers will also collect blood samples to analyze serum creatinine and calculate estimated glomerular filtration rate (eGFR). A significant decline in eGFR indicates worsening kidney function. The study will include participants who had previously participated in FIONA study (NCT05196035). The participants will be aged from 1 year up to 18 years. The participants will be in the study for approximately 19 months. They will take study treatment for up to 18 months and will be follow up for 1 month. During this period, at least 12 visits are planned for patients who newly start finerenone, and at least 8 visits for patients who already received finerenone. In the visit, the study team will: * have their blood pressure, heart rate, temperature, height and weight measured * have blood and urine samples taken * have physical examinations * have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart) * answer questions about their medication and whether they have any adverse events, or have their parents or guardian's answer * answer questions about how they are feeling, or have their parents or guardian's answer * answer question about how they like the study medication, or have their parents or guardian's answer The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The doctors will check the participants' health about 30 days after the participants take their last treatment.

Conditions

  • Chronic Kidney Disease
  • Proteinuria
  • Children

Interventions

  • Finerenone (Kerendia, BAY94-8862)Drug

    Finerenone in different doses, treatment duration will be 540 ±7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse event (TEAEs)Time frame: Up to 550 days
  2. Change in serum potassium levels from baseline to Day 540±7Time frame: Up to 547 days
  3. Change in systolic blood pressure (SBP) from baseline to Day 540±7Time frame: Up to 547 days

Locations

151 sites in 32 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital | Main - Transplant Department

    Phoenix, Arizona · Withdrawn

  • Cedars-Sinai Samuel Oschin Cancer Center

    Los Angeles, California · Withdrawn

  • Lucille Packard Children's Hospital Stanford - Pediatric Nephrology

    Palo Alto, California · Active not recruiting

  • Rady Children's Hospital San Diego - Cardiology

    San Diego, California · Withdrawn

  • Children's National Hospital - Nephrology

    Washington D.C., District of Columbia · Withdrawn

  • Memorial Transplant Institute - Pediatric Nephrology

    Hollywood, Florida · Withdrawn

  • Emory University Hospital/Children's Healthcare of Atlanta - Nephrology

    Atlanta, Georgia · Withdrawn

  • University of Iowa Health Care Medical Center - Nephrology

    Iowa City, Iowa · Withdrawn

  • The Charlotte R. Bloomberg Children's Center Building - Nephrology

    Baltimore, Maryland · Active not recruiting

  • Boston Children's Hospital - Main Campus - Nephrology

    Boston, Massachusetts · Withdrawn

  • Children's Mercy Hospital Kansas City - Nephrology

    Kansas City, Missouri · Withdrawn

  • Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension

    Cincinnati, Ohio · Withdrawn

  • Cleveland Clinic | Pediatric Nephrology

    Cleveland, Ohio · Completed

  • OHSU Doernbecher Children's Hospital - Neurology

    Portland, Oregon · Withdrawn

  • Children's Hospital of Philadelphia - Nephrology

    Philadelphia, Pennsylvania · Withdrawn

  • University Hospital - San Antonio - Pediatric Nephrology

    San Antonio, Texas · Withdrawn

  • Eccles Primary Children's Outpatient Services - Nephrology

    Salt Lake City, Utah · Active not recruiting

  • Seattle Children's Hospital - Nephrology

    Seattle, Washington · Withdrawn

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Active not recruiting

  • Hospital de Pediatría Juan P. Garrahan

    Buenos Aires, Argentina · Withdrawn

  • Hospital General de Ninos Pedro de Elizalde | Nephrology Department

    Buenos Aires, Argentina · Active not recruiting

  • Hospital General de Ninos Ricardo Gutierrez | Pediatric Nephrology Department

    Buenos Aires, Argentina · Recruiting

  • Centro de Rehabilitacion Cardiovascular | San Luis, Argentina

    San Luis, Argentina · Active not recruiting

  • Clinica de Nefrologia, Urologia y Enfermedades Cardiovascualares | Santa Fe, Argentina

    Santa Fe, Santa Fe Province, Argentina · Withdrawn

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia · Active not recruiting

  • Monash Children's Hospital

    Clayton, Victoria, Australia · Withdrawn

  • Royal Children's Hospital Melbourne

    Parkville, Victoria, Australia · Recruiting

  • Uniklinikum Salzburg - Landeskrankenhaus

    Vienna, State of Vienna, Austria · Withdrawn

  • Universitätsklinikum AKH Wien

    Vienna, State of Vienna, Austria · Withdrawn

  • Medizinische Universität Graz, Landeskrankenhaus-Universitätsklinikum Graz

    Graz, Styria, Austria · Withdrawn

  • Kepler Universitätsklinikum Campus IV

    Innsbruck, Tyrol, Austria · Completed

  • CHC Montlégia - Pediatrics

    Liège, Belgium · Withdrawn

  • Huderf / Ukzkf

    Brussels, Brussels Capital, Belgium · Withdrawn

  • CU Saint-Luc/UZ St-Luc

    Brussels, Brussels Capital, Belgium · Withdrawn

  • UZ Gent

    Ghent, East Flanders, Belgium · Active not recruiting

  • UZ Gasthuisberg - Pediatric Nephrology

    Leuven, Flemish Brabant, Belgium · Completed

  • Hospital Infantil Sabará - Instituto PENSI - Pesquisa e Ensino em Saúde Infantil

    São Paulo, Brazil · Withdrawn

  • Instituto da Crianca e do Adolescente

    São Paulo, Brazil · Not yet recruiting

  • Hospital PUC-Campinas | Centro de Pesquisa Clínica Sao Lucas

    São Paulo, Brazil · Recruiting

  • Santa Casa de Misericórdia de Belo Horizonte

    São Paulo, Brazil · Recruiting

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.